Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

251.64 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jun 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
From Biotech Insider
Via GlobeNewswire
News headline image
This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy? ↗
AbbVie knows how to plan ahead. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 No-Brainer Dividend Stocks to Buy Right Now ↗
AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market. 
Via The Motley Fool
Topics Intellectual Property
News headline image
AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy? ↗
In the past five years, this top healthcare stock has risen by close to 130%. 
Via The Motley Fool
AbbVie Inc (NYSE:ABBV) Breakout Setup Combines Strong Technical Rating with High-Quality Consolidation Entry ↗
Via Chartmill
News headline image
2 S&P 500 Stocks with Promising Prospects and 1 We Find Risky
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ... 
Via StockStory
Topics Retirement Stocks
News headline image
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026? ↗
AbbVie and Pfizer are taking divergent paths to navigate patent expirations and competition. Dig into their financials, risk profiles, and valuation metrics. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Is AbbVie a Buy After Its Purchase of Apogee? ↗
The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion? 
Via The Motley Fool
News headline image
The Aesthetics Giants Just Confirmed “Ozempic Face” Is Real — and a Newly Public Regenerative Player Wants to Compete for It
From Biotech Insider
Via GlobeNewswire
News headline image
Here’s How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years ↗
AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 4.21% on an annualized basis producing an average annual return of 15.79%. Currently, AbbVie has a market capitalization of... 
Via Benzinga
News headline image
2 Value Stocks Worth Your Attention and 1 Facing Headwinds
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t... 
Via StockStory
News headline image
3 Monster Stocks to Hold for the Next 10 Years ↗
These healthcare stocks may be the building blocks of a winning portfolio. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Why AbbVie Stock Jumped Today ↗
An intriguing acquisition could bring exciting new drugs into the medicine maker's development pipeline. 
Via The Motley Fool
News headline image
AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King? ↗
The company is already renowned by many as a giant in the segment. 
Via The Motley Fool
Monday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG)
From Brodsky & Smith LLC
Via GlobeNewswire
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
News headline image
5 Dividend Stocks to Buy and Hold Forever ↗
Get rich slowly. How? Hold these stocks and reinvest the dividends they pay. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Excellent Dividend Stocks to Buy on the Dip ↗
Don't wait too long to get in on these outstanding dividend payers. 
Via The Motley Fool
Topics Artificial Intelligence Economy Intellectual Property
News headline image
2 Profitable Stocks Worth Your Attention and 1 We Avoid
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
Via StockStory
News headline image
How Many Botox Units Do You Need: Forehead, Crow's Feet, and Frown Lines
Via Press Release Distribution Service
News headline image
3 High-Yield Dividend Stocks to Buy Hand Over Fist in June ↗
Now's the time to load up on these high-yielders. 
Via The Motley Fool
Topics Economy
News headline image
Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock? ↗
Driving revenue growth and earnings growth are two different things. 
Via The Motley Fool
Topics Intellectual Property
News headline image
AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend. ↗
New cancer therapies may help fund dividend growth. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500? ↗
For a solid yield and strong upside potential, this pharmaceutical stock is worth considering. 
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
The Best Stocks to Invest $500 in Right Now ↗
The market is underestimating these companies' long-term prospects. 
Via The Motley Fool
News headline image
Dry eye syndrome drugs Market Size, Industry Report By 2035 ↗
The most recent research report on the "Dry eye syndrome drugs Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic foreca 
Via Talk Markets
Topics Economy
News headline image
Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Year, According to Wall Street ↗
Wall Street analysts expect market-beating returns from healthcare and communication services stocks over the next year. 
Via The Motley Fool
Topics ETFs Intellectual Property Stocks
News headline image
Higher Yield or Broader Dividend Diversification? VYM vs. HDV ↗
The Vanguard High Dividend Yield ETF (VYM) and the iShares Core High Dividend ETF (HDV) both provide exposure to U.S. dividend equities, but their income profiles are built differently. For investors... 
Via The Motley Fool
Topics ETFs
News headline image
Johnson & Johnson Hopes to Dethrone AbbVie's Biggest Growth Driver. Here's Why Investors Shouldn't Panic ↗
AbbVie's shareholders can sleep easy. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.